Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients

Kweku A. Appau, Victor W. Fazio, Bo Shen, James M. Church, Bret Lashner, Feza Remzi, Aaron Brzezinski, Scott A. Strong, Jeffrey Hammel, Ravi P. Kiran

Research output: Contribution to journalArticlepeer-review

201 Scopus citations

Fingerprint Dive into the research topics of 'Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients'. Together they form a unique fingerprint.

Medicine & Life Sciences